PRAXIS

- with a global prevalence of \sim 65 million people.
- uncontrolled seizures.
- unexpected death in epilepsy (SUDEP) and seizure-related accidents.
- epilepsy journey; and help identify subjects for Praxis clinical trials.

- personal information (e.g., age, gender, etc.)
- prospectively tracking intercurrent events (e.g. hospitalizations, infections).
- experiences.
- 2023 to 31 December 2024.





- 1. CDC 2015 US Prevalence Data 2. Gupta et al 2017 Epilepsia Open
- 3. Seiden & Connor 2022 Epilepsy & Behavior

Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): An Observational Study Designed to Better Understand the Patient Journey


Funding Medical writing and editorial assistance were provided by Lillian G. Matthews in accordance with Good Publication Practice (GPP3).

Disclosures KH, SF, BG, SP, MS and JF are current or former employees/consultants of Praxis Precision Medicines and may be Praxis shareholders

Karl Hansen¹, <u>Silvana Frizzo¹</u>, Brittany Gazdag¹, Jack Mead², Steven Petrou¹, Marcio Souza¹, Jacqueline French² ¹Praxis Precision Medicines, Boston, MA, USA; ²Ambit Inc, Boston, MA, USA; ³NYU Comprehensive Epilepsy Center, New York, NY, USA

X @PraxisMedicines

- Praxismedicines.com
- Praxis Precision Medicines
- clinicaltrials@praxismedicines.com





Presented at: American Academy of Neurology AAN 2025 Annual Meeting April 5-9, 2025 San Diego, California USA